Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Rhabdoid Tumor 3Pinealoma 3Neuroectodermal Tumors, Primitive 3Neoplasms, Germ Cell and Embryonal 3Medulloblastoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Glioma 3Ependymoma 3Choroid Plexus Carcinoma 3Central Nervous System Neoplasms 3Brain Neoplasms 3Lymphoma, Follicular 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Diffuse Intrinsic Pontine Glioma 1Dendritic Cell Sarcoma, Interdigitating 1CD7-Positive Hematological Malignancies 1Burkitt Lymphoma 1

Interventions

Rituximab 45Cyclophosphamide 38ibrutinib 22fludarabine 22acalabrutinib 21venetoclax 20zanubrutinib 17Lenalidomide 17Bendamustine Hydrochloride 17obinutuzumab 16fludarabine phosphate 14Magnetic Resonance Spectroscopy 14Cytarabine 14Specimen Handling 13CT-P10 13pirtobrutinib 12Biopsy 12glofitamab 10Etoposide 10Whole-Body Irradiation 9Vincristine 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Melphalan 7Doxorubicin 7brexucabtagene autoleucel 6Cyclosporine 6orelabrutinib 5Methotrexate 5Immunotherapy, Adoptive 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × Automobiles × 1 year × Clear all
NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 1 Recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡